CONTEXT Hypothalamic hamartoma (HH) represents the commonest cause of organic central precocious puberty (CPP). Follow-up of these patients at adulthood are scarce. OBJECTIVE To describe the anthropometric, metabolic and reproductive parameters of patients with CPP due to HH before and after treatment with gonadotropin-releasing hormone analog (GnRHa). DESIGN Retrospective and cross-sectional study. SETTING Single tertiary center. PARTICIPANTS Fourteen patients (7 females) with CPP due to HH. RESULTS The mean duration of GnRHa treatment was 7.7 ± 2.4 year in boys and 7.9 ± 2.1 year in girls. GnRHa treatment was interrupted at the mean chronological age (CA) 12.1 ± 1.1 year in boys and 10.7 ± 0.5 year in girls. At the last visit, the mean CA of the male and female patients was 21.5 ± 3.2 and 24 ± 3.9 year, respectively. Eleven of 14 patients reached normal final height (SDS -0.6 ± 0.9 for males and -0.6 ± 0.5 for females), all of them within target height (TH) range. The remaining three patients had predicted height within TH range. Mean BMI and the percentage of body fat mass was significantly higher in females, with a higher prevalence of metabolic disorders. All patients presented normal gonadal function at adulthood, and 3 males fathered a child. CONCLUSION All patients with CPP due to HH reached normal final or near final height. A higher prevalence of overweight/obesity and hypercholesterolemia was observed in the female patients. Finally, no reproductive disorder was identified in both sexes, indicating that HH per se has no deleterious effect on gonadotropic axis at adulthood.